awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q58794894-1AD44DA6-25C6-49AB-89F9-8DB896583A49
Q58794894-1AD44DA6-25C6-49AB-89F9-8DB896583A49
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58794894-1AD44DA6-25C6-49AB-89F9-8DB896583A49
Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types
P2860
Q58794894-1AD44DA6-25C6-49AB-89F9-8DB896583A49
BestRank
Statement
http://www.wikidata.org/entity/statement/Q58794894-1AD44DA6-25C6-49AB-89F9-8DB896583A49
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d5465f428864e6913b7c65bd8982d83ee6455305
P2860
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.